Therefore we did a trial in hysterectomised women of tamoxifen as a chemopreventive. Women were randomised to receive tamoxifen 20 mg per day or placebo, both orally for 5 years. The original plan was to follow the intervention phase by 5 years' follow-up. The primary endpoints are the occurrence of and deaths from breast cancer. Compared with the placebo group, there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen.
Women using hormone-replacement therapy appear to have benefited from use of tamoxifen.
There were no deaths from breast cancer recorded in women in the study. AN 98221039 AU Bruzzi P. TI Tamoxifen for the prevention of breast cancer.